Navigation Links
Aortic Stent Grafts Will Boost Canadian and Japanese Peripheral Vascular Markets
Date:6/19/2008

Japanese and Canadian aortic stent graft market to grow at CAGRs of nearly 60% and 20%, respectively, through 2012, according to Millennium Research

Group

WALTHAM, Mass., June 19 /PRNewswire/ -- According to Millennium Research Group's Japanese Markets for Peripheral Vascular (PV) Devices 2008 report, the aortic stent graft market will increase at a compound annual growth rate (CAGR) of nearly 60% through 2012 due to market entry of both abdominal and thoracic stent grafts in 2006 and 2008, respectively. These new devices and a growing physician preference for minimally invasive procedures will also be key drivers. While growth will not be as high as in Japan, the more established Canadian stent graft market will also expand significantly, at a CAGR of close to 20% through 2012.

In both Canada and Japan, continued introduction of innovative stent graft technologies will allow more patients with aortic disease to be treated using endovascular techniques rather than surgery. For instance, in June 2008, W.L. Gore's TAG was the first thoracic stent graft to receive regulatory approval in Japan. The first abdominal stent grafts were approved in 2006. Procedures will experience robust growth over the next five years as new devices are introduced into the Japanese and Canadian markets, extending the treatable patient population. Successful aortic repair using stent grafts has encouraged Japanese and Canadian physicians to adopt the procedures, expanding procedures and revenues in both countries.

"Device innovation is improving the success rates of aortic stent grafts while also expanding the treatable patient population," says Ryan Brown, Analyst at Millennium Research Group. "As these devices become increasingly available in relatively underpenetrated markets, growing patient awareness of and demand for minimally invasive aortic procedures will drive the adoption of aortic stent grafts."

The Japanese and Canadian Markets for Peripheral Vascular Devices 2008 reports provide coverage of all key industry competitors, including Boston Scientific, Cook Medical, Cordis, Terumo, and W.L. Gore, among others. Global coverage of this report also includes US, Europe, Asia Pacific, and Latin America.

About Aortic Stent Grafts

The aorta, the main artery leaving the heart, splits into two iliac arteries that transport blood to the lower extremities. An aneurysm (the weakening and bulging of a blood vessel or artery) directly above the iliac bifurcation is referred to as an abdominal aortic aneurysm (AAA); one located in the ascending aorta, aortic arch, or the descending thoracic aorta is referred to as a thoracic aortic aneurysm (TAA). Stent grafts, tubes composed of fabric supported by a metal mesh, are designed to fasten tightly to the artery above and below the aneurysm. Once in place, blood passes through the stent graft rather than pushing on the bulge of the aneurysm.

About Millennium Research Group

Millennium Research Group (http://www.MRG.net), a Decision Resources, Inc. company (http://www.DecisionResources.com), is the global authority on medical technology market intelligence and a leading provider of strategic information to the health care sector. Focused solely on the medical device, pharmaceutical, and biotechnology industries, the company provides its clients with the benefits of its specialized industry expertise through published reports and customized consulting services.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Amy Krohn

Millennium Research Group

416-364-7776 x101

akrohn@mrg.net


'/>"/>
SOURCE Millennium Research Group
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Boston Scientific Announces Sale of TriVascular Endovascular Aortic Repair Program
2. ATS Medical Announces First North American Commercial Implant of the ATS 3f Aortic Bioprosthesis
3. ES Vascular Receives CE Mark for its First Aortic Stapler for End-to-End Anastomosis Between Synthetic Grafts and Aorta During Open Repair of Aortic Aneurysmal and Occlusive Disease
4. Safety Profile of TAXUS(R) Liberte(TM) Stent System Highlighted in Worlds Largest Stent Registry
5. Preclinical Research on Coronary Stent with CeloNova BioSciences Polyzene(R)- F Nanocoating Receives Award at CIRSE 2007
6. ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients
7. PCI Guideline Update Stresses Long-Term Anticoagulant Therapy After Treatment With Drug-Eluting Stents
8. Biosensors Receives CE Mark Approval for Its BioMatrix(R) Drug-Eluting Coronary Stent System
9. CV Therapeutics and Medlogics Device Corporation Sign Licensing Agreement for CVTs Innovative Stent Coating Technology
10. Tryton Medical Receives CE Mark Approval for its Side-Branch Stent
11. Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2016)... June 22, 2016  According to Kalorama Information, ... sequencing (NGS) market include significant efforts in automation ... More accessible and affordable sequencers, say the healthcare ... for consumables including sample prep materials.  The healthcare ... Sample Preparation for Next Generation Sequencing (NGS) , ...
(Date:6/22/2016)...   ViaCyte, Inc. , a privately-held regenerative medicine ... therapy for the treatment of diabetes in clinical-stage development, ... ISSCR 2016, the Global Stem Cell Event, is taking ... San Francisco.    ... , Focus Session: Tools for Basic and Applied Stem ...
(Date:6/22/2016)... DIEGO , June 22, 2016  Mesa ... has developed a testing platform designed specifically for ... formation of their scientific advisory board (SAB). Approved ... directors, the SAB is chartered to advise on ... disease assay platform. Led by Dr. Steve ...
(Date:6/21/2016)... , China , June 22, 2016 ... Phase 2 clinical trial for its novel patch product ... (p=0.023) and clinically meaningful pain relief against placebo. Conducted ... States , the trial enrolled 146 patients with ... (1) analgesia against placebo at week-1 (p=0.024), (2) greater ...
Breaking Biology Technology:
(Date:6/7/2016)... 7, 2016  Syngrafii Inc. and San Antonio ... that includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" ... collaboration will result in greater convenience for SACU ... while maintaining existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/1/2016)... , June 1, 2016 Favorable ... Election Administration and Criminal Identification to Boost Global Biometrics ... recently released TechSci Research report, " Global Biometrics Market ... Competition Forecast and Opportunities, 2011 - 2021", the global ... by 2021, on account of growing security concerns across ...
(Date:5/9/2016)... 9, 2016 Elevay is currently ... expanding freedom for high net worth professionals seeking travel ... globally connected world, there is still no substitute for ... duplicate sealing your deal with a firm handshake. This ... taking advantage of citizenship via investment programs like those ...
Breaking Biology News(10 mins):